AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported a second-quarter earnings per share (EPS) of $(0.18), beating the analyst consensus estimate of $(0.27) by 33.33 percent. This result represents a 14.29 percent increase in losses compared to the $(0.21) per share loss recorded in the same period last year. Despite the wider net loss of $8.2 million for the quarter ended June 30, 2026, the company’s performance exceeded market expectations, driven by disciplined cost management and strategic capital allocation toward its clinical pipeline.

The improved per-share metric contrasts with the absolute widening of the net loss from $6.5 million in Q2 2025 to $8.2 million in Q2 2026. This divergence highlights the impact of share count adjustments or other income factors not fully captured by the headline loss figure. Management attributed the increased burn rate to accelerated investments in its boron chemistry platform, specifically advancing start-up activities for three Phase 2 clinical trials. General and administrative (G&A) expenses declined to $2.9 million from $4.0 million year-over-year, offsetting a rise in research and development (R&D) costs to $6.0 million from $3.2 million.

Pipeline Progress Updates

AN2 Therapeutics is expanding its clinical footprint across hematologic, infectious, and oncologic diseases. Key developments include:

• Polycythemia Vera: Following a pre-IND meeting with the FDA, the company plans to expand its global Phase 2 trial (EBO-PV-201) of oral epetraborole to include sites in the U.S. and Australia. An IND filing is expected in the third quarter of 2026, with enrollment anticipated to commence in the fourth quarter of 2026.
• M. abscessus Lung Disease: Enrollment is ongoing in an investigator-initiated Phase 2 study led by Dr. Kevin Winthrop at Oregon Health and Sciences University. The 84-patient multicenter study aims to provide clinical proof-of-concept, with topline results expected in late 2027.
• Chronic Chagas Disease: Positive non-human primate efficacy data and favorable Phase 1 safety profiles support the planned initiation of a Phase 2 proof-of-concept study for AN2-502998 by late 2026. The compound demonstrated 100% parasitic elimination in NHPs with naturally acquired infections.
• Oncology: The company declared ENPP1 as its first development candidate for solid tumors earlier this year and expects to advance a second candidate by the end of 2026.

Financial Highlights

What the Numbers Show

The beat on EPS estimates despite a wider absolute net loss suggests effective capital efficiency or favorable non-operational adjustments. While R&D expenses surged 87.5% due to higher chemistry manufacturing and controls (CMC) costs and clinical trial preparations, G&A costs fell 27.5%, indicating successful operational leverage. With $79.9 million in cash, cash equivalents, and investments as of June 30, 2026, AN2 Therapeutics projects sufficient liquidity to sustain operations into 2029, reducing immediate pressure for dilutive financing despite the elevated burn rate associated with multi-program Phase 2 initiations.

Guggenheim analyst Brad Canino has initiated coverage on AN2 Therapeutics with a Buy rating and a price target of $9. The rating reflects a positive outlook on the company's performance and potential in the market.

The price target of $9 provides a specific valuation benchmark for investors evaluating the stock. This initiation marks the beginning of formal coverage by the firm.